

KEVZARA (sarilumab) [non-preferred] PRIOR AUTHORIZATION FORM

Cytokine and CAM Antagonists and Quantity Limits/Daily Dose Limits prior authorization guidelines are accessible on the DHS Pharmacy Services website at <http://www.dhs.pa.gov/provider/pharmacyservices/index.htm>.

PRIOR AUTHORIZATION REQUEST INFORMATION			PRESCRIBER INFORMATION		
<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request	# of pages: _____	Prescriber name:		
Name of office contact:			Specialty:		
Contact's phone number:			State license #:		
LTC facility contact/phone:			NPI:	MA Provider ID#:	
BENEFICIARY INFORMATION			Street address:		
Beneficiary name:			Suite #:	City/state/zip:	
Beneficiary ID#:	DOB:	Phone:	Fax:		

CLINICAL INFORMATION

Product requested:	<input type="checkbox"/> Kevzara 150 mg/1.14 ml syringe	<input type="checkbox"/> Kevzara 200 mg/1.14 ml syringe	<input type="checkbox"/> Kevzara: _____
	<input type="checkbox"/> Kevzara 150 mg/1.14 ml pen injector	<input type="checkbox"/> Kevzara 200 mg/1.14 ml pen injector	
Directions:	Quantity:	Refills:	
Diagnosis (<u>submit documentation</u>):	Diagnosis code (<u>required</u>):		
Specialty Pharmacy Drug Program: Which specialty pharmacy will be used? <input type="checkbox"/> Diplomat Specialty <input type="checkbox"/> Walgreen's Specialty			

INITIAL requests

1. Check all that apply to the beneficiary and <u>submit documentation for each</u> .		
<input type="checkbox"/> vaccinated for hepatitis B	<input type="checkbox"/> screened for hepatitis B (surface antigen & core antibody)	<input type="checkbox"/> has been using Kevzara in the past 90 days
<input type="checkbox"/> screened for tuberculosis	<input type="checkbox"/> up-to-date with all age-appropriate immunizations	
2. Does the beneficiary have active hepatic disease or hepatic impairment?	<input type="checkbox"/> Yes	<i>Submit documentation.</i>
	<input type="checkbox"/> No	
3. Does the beneficiary have a history of trial and failure, contraindication, or intolerance of <u>at least 3 months</u> of treatment with methotrexate or another DMARD?	<input type="checkbox"/> Yes	<i>Submit documentation of all medications tried and outcomes.</i>
	<input type="checkbox"/> No	
4. Does the beneficiary have a history of trial and failure, contraindication, or intolerance of the preferred agents? <i>Check all that apply.</i>	<input type="checkbox"/> Yes	<i>Submit documentation of all medications tried and outcomes.</i>
<input type="checkbox"/> Humira <input type="checkbox"/> Xeljanz	<input type="checkbox"/> No	
5. <u>For a diagnosis other than the approved indication(s)</u> , submit documentation supporting the use of Kevzara for the beneficiary's diagnosis & other treatments tried.		

RENEWAL requests

1. Since starting Kevzara, did the beneficiary experience a positive clinical response and/or improved level of functioning?	<input type="checkbox"/> Yes	<i>Submit documentation of clinical response.</i>
	<input type="checkbox"/> No	
2. Does the beneficiary have active hepatic disease or hepatic impairment?	<input type="checkbox"/> Yes	<i>Submit documentation.</i>
	<input type="checkbox"/> No	

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION

Prescriber Signature:	Date:
------------------------------	--------------

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.